Dublin, Ireland; 4/10/2013


GMR Data forecast that the global smoking cessation market is set to reach $4.4bn by 2023.


'Smoking Cessation - Data, Analysis & Forecasts to 2023' is GMR Data’s latest Pharma report. Primary drivers of the global smoking cessation market include; high global prevalence of smoking, increased public awareness of smoking related health implications alongside increased re-imbursement of anti-smoking products via medical insurance / national health programmes.

The 'Smoking Cessation - Data, Analysis & Forecasts to 2023' report analyses how this important, developing market will grow over the next ten years. The report quantifies the market in terms of global size and breaks the market down into key leading countries; EU5, US, Japan & ROW, with forecasts and analysis provided for each of these markets from 2013-2023. The report also examines the major drivers and restraints influencing the smoking cessation market over the next decade and outlines the key drugs and treatments currently in the market place.


GMR Data’s 'Smoking Cessation - Data, Analysis & Forecasts to 2023' report details the prospects for this dynamic pharmaceutical sector with detailed forecasts from 2013-2023. The report will be valuable to those already involved in the smoking cessation market or to those wishing to enter this important market in the future.


The 'Smoking Cessation - Data, Analysis & Forecasts to 2023' report includes over 85 tables, charts and graphs quantifying and forecasting the smoking cessation market in detail. In addition, the report offers profiles of the leading producers of smoking cessation products, drugs and devices on the market.

This report also contains with 3 exclusive interviews with;


  • Pfizer
  • Elder Pharmaceuticals
  • GlaxoSmithKline


For additional information regarding this, or any other GMR Data report please contact info@gmrdata.com or visit gmrdata.com